NasdaqGS:ALXN

Stock Analysis Report

Executive Summary

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.


Snowflake Analysis

Outstanding track record and undervalued.


Similar Companies

Share Price & News

How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALXN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.4%

ALXN

0.3%

US Biotechs

-4.1%

US Market


1 Year Return

-36.0%

ALXN

-0.6%

US Biotechs

-14.9%

US Market

Return vs Industry: ALXN underperformed the US Biotechs industry which returned -1.1% over the past year.

Return vs Market: ALXN underperformed the US Market which returned -13.6% over the past year.


Shareholder returns

ALXNIndustryMarket
7 Day7.4%0.3%-4.1%
30 Day-7.1%-8.1%-19.1%
90 Day-15.1%-5.3%-23.4%
1 Year-36.0%-36.0%0.2%-0.6%-13.2%-14.9%
3 Year-21.9%-21.9%14.5%11.6%10.7%3.5%
5 Year-50.5%-50.5%-6.9%-11.1%28.5%14.5%

Price Volatility Vs. Market

How volatile is Alexion Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alexion Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALXN ($90.35) is trading below our estimate of fair value ($198.69)

Significantly Below Fair Value: ALXN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALXN is good value based on its PE Ratio (8.4x) compared to the Biotechs industry average (16x).

PE vs Market: ALXN is good value based on its PE Ratio (8.4x) compared to the US market (12.9x).


Price to Earnings Growth Ratio

PEG Ratio: ALXN is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: ALXN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (2.7x).


Next Steps

Future Growth

How is Alexion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALXN's forecast earnings growth (7.2% per year) is above the savings rate (1.7%).

Earnings vs Market: ALXN's earnings (7.2% per year) are forecast to grow slower than the US market (12.3% per year).

High Growth Earnings: ALXN's earnings are forecast to grow, but not significantly.

Revenue vs Market: ALXN's revenue (7.5% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: ALXN's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALXN's Return on Equity is forecast to be low in 3 years time (16.5%).


Next Steps

Past Performance

How has Alexion Pharmaceuticals performed over the past 5 years?

30.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALXN has high quality earnings.

Growing Profit Margin: ALXN's current net profit margins (48.2%) are higher than last year (1.9%).


Past Earnings Growth Analysis

Earnings Trend: ALXN's earnings have grown significantly by 30% per year over the past 5 years.

Accelerating Growth: ALXN's earnings growth over the past year (2998.3%) exceeds its 5-year average (30% per year).

Earnings vs Industry: ALXN earnings growth over the past year (2998.3%) exceeded the Biotechs industry 22%.


Return on Equity

High ROE: ALXN's Return on Equity (21.3%) is considered high.


Next Steps

Financial Health

How is Alexion Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ALXN's short term assets ($5.1B) exceed its short term liabilities ($1.2B).

Long Term Liabilities: ALXN's short term assets ($5.1B) do not cover its long term liabilities ($5.1B).


Debt to Equity History and Analysis

Debt Level: ALXN's debt to equity ratio (22.7%) is considered satisfactory.

Reducing Debt: ALXN's debt to equity ratio has increased from 1.7% to 22.7% over the past 5 years.

Debt Coverage: ALXN's debt is well covered by operating cash flow (81.3%).

Interest Coverage: ALXN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: ALXN has a low level of unsold assets or inventory.

Debt Coverage by Assets: ALXN's debt is covered by short term assets (assets are 2x debt).


Next Steps

Dividend

What is Alexion Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALXN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALXN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALXN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALXN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Ludwig Hantson (56yo)

3.08s

Tenure

US$18,947,984

Compensation

Dr. Ludwig N. Hantson, Ph.D., has been Chief Executive Officer at Alexion Pharmaceuticals, Inc. since March 27, 2017. Dr. Hantson has been the President of Synovis Life Technologies Inc. since February 14, ...


CEO Compensation Analysis

Compensation vs Market: Ludwig's total compensation ($USD18.95M) is above average for companies of similar size in the US market ($USD11.86M).

Compensation vs Earnings: Ludwig's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ludwig Hantson
CEO & Director3.08yrsUS$18.95m0.042% $8.4m
Brian Goff
Executive VP and Chief Commercial & Global Operations Officer0.50yrUS$5.55m0.0089% $1.8m
Anne-Marie Law
Executive VP & Chief Human Experience Officer2.83yrsUS$5.14m0.0054% $1.1m
John Orloff
Executive VP and Head of Research & Development2.83yrsUS$5.63m0.0056% $1.1m
Paul Clancy
Executive VP & Senior Advisor0.50yrUS$5.87m0.021% $4.3m
Aradhana Sarin
Executive VP & CFO0.50yrUS$4.88m0.0047% $943.1k
Daniel Bazarko
Chief Accounting Officer & Senior VPno datano data0.0063% $1.3m
Susan Altschuller
Vice President of Investor Relationsno datano datano data
Indrani M. Franchini
Executive VP & Chief Compliance Officer2.83yrsno data0.0046% $931.1k
Ellen Chiniara
Executive VP2.17yrsno data0.0020% $397.3k

2.5yrs

Average Tenure

54yo

Average Age

Experienced Management: ALXN's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ludwig Hantson
CEO & Director3.08yrsUS$18.95m0.042% $8.4m
Felix Baker
Independent Director4.83yrsUS$470.05k0.059% $11.9m
Paul Friedman
Independent Director2.58yrsUS$445.05k0.0019% $375.2k
Christopher Coughlin
Director5.75yrsUS$630.11k0.013% $2.5m
Deborah Dunsire
Independent Director2.25yrsUS$445.07k0.0022% $435.4k
David Brennan
Independent Chairman of the Board2.92yrsUS$595.05k0.0028% $553.8k
Judith Reinsdorf
Independent Director2.17yrsUS$470.01k0.0021% $417.4k
Andreas Rummelt
Independent Director10.17yrsUS$445.05k0.0087% $1.8m
John Mollen
Independent Director6yrsUS$470.05k0.0023% $455.5k
Francois Nader
Independent Director2.42yrsUS$445.05k0.0019% $375.2k

3.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ALXN's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alexion Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alexion Pharmaceuticals, Inc.
  • Ticker: ALXN
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.067b
  • Shares outstanding: 222.10m
  • Website: https://www.alexion.com

Number of Employees


Location

  • Alexion Pharmaceuticals, Inc.
  • 121 Seaport Boulevard
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALXNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1996
AXPXTRA (XETRA Trading Platform)YesCommon StockDEEURFeb 1996
AXPDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1996
ALXNSWX (SIX Swiss Exchange)YesCommon StockCHCHFFeb 1996
0QZMLSE (London Stock Exchange)YesCommon StockGBUSDFeb 1996
ALXN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNFeb 1996
ALXNWBAG (Wiener Boerse AG)YesCommon StockATEURFeb 1996
AXP-UETLX (Eurotlx)YesCommon StockITEURFeb 1996
A1LX34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REPR 2 COMBRBRLDec 2019

Biography

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 00:34
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.